Is Ubiome introducing a new biomarker or diagnostic for ME? "The patented technology involves diagnosing an endocrine system condition such as chronic fatigue syndrome, Graves’ disease, Hashimoto’s thyroiditis, metabolic disease, obesity, and Type I and II diabetes, and generating a therapy model using biological samples from uBiome’s proprietary database." https://www.prweb.com/releases/ubio...endocrine_system_conditions/prweb15995198.htm
Patents are written to cover as many applications as possible. It doesn't mean that uBiome knows something that we don't.
I wonder which criterion they are using. If it is Fukuda, forget it. And, since it says CFS, I bet it is.
My reading of this, which may be wrong, is that the thing they are patenting is their database of microbiome data, presumably derived from samples from patients with these conditions. Edit: and any tests they develop using the database??
I wonder how they even know? I have used Ubiome multiple times and it has never asked me if I have CFS.
I don't think we can say that Fukuda is inferior to the CCC and ICC. The ICC and CCC tend to select ME/CFS patients with more severe impairments (and also select for patients with more psychiatric comorbidities) compared to Fukuda; 1 2 but in some ways that may put the ICC and CCC at a disadvantage, in that they may miss the milder cases. Moderator note: This post has been copied to a new thread in the Diagnostic Guidelines sub-forum: comparison-of-diagnostic-criteria-discussion-thread Subsequent posts on this topic have been moved to the new thread. Please continue any further discussion about diagnostic criteria on the new thread.
Just because it is patented doesn't mean it works, there are for example hundreds of patents for perpetual motion machines.
